These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 5003621)

  • 41. Alkylating agents in bronchogenic carcinoma.
    Green RA; Humphrey E; Close H; Patno ME
    Am J Med; 1969 Apr; 46(4):516-25. PubMed ID: 5791000
    [No Abstract]   [Full Text] [Related]  

  • 42. Contributions of nitrosoureas to cancer treatment.
    Mitchell EP; Schein PS
    Cancer Treat Rep; 1986 Jan; 70(1):31-41. PubMed ID: 3002621
    [No Abstract]   [Full Text] [Related]  

  • 43. Phase I clinical trial of isophosphamide (NSC-109724).
    Cohen MH; Creaven PJ; Tejada F; Hansen HH; Muggia F; Mittelman A; Selawry OS
    Cancer Chemother Rep; 1975; 59(4):751-5. PubMed ID: 1100226
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Cytostatic therapy with Trenimon].
    Mayerhofer S
    Munch Med Wochenschr; 1965 Sep; 107(37):1776-83. PubMed ID: 5325207
    [No Abstract]   [Full Text] [Related]  

  • 45. [Cytostatic treatment with a combination of vincristine and ifosfamide].
    Hartwich G; Tschätsch W; Lutz H
    Dtsch Med Wochenschr; 1973 Jun; 98(24):1203-7. PubMed ID: 4708299
    [No Abstract]   [Full Text] [Related]  

  • 46. Toxicity study of BCNU (NSC-409962) given orally.
    Lessner HE; Vogler WR
    Cancer Chemother Rep; 1974; 58(3):407-11. PubMed ID: 4601671
    [No Abstract]   [Full Text] [Related]  

  • 47. Enzyme alterable alkylating agents. 8. Clinical trials with intra-arterial infusion of an alkylating agent with a half-life of 0.2 second.
    Goodman LE; Ulfohn A; Kramer SP; Cendana EH; Flores AB; Bakal D; Abrams SJ; Hirschfeld RL; Calle S; Williamson CE; Sass S; Witten B; Seligman AM
    Ann Surg; 1965 Oct; 162(4):663-89. PubMed ID: 5319397
    [No Abstract]   [Full Text] [Related]  

  • 48. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.
    Rege VB; Owens AH
    Cancer Chemother Rep; 1974; 58(3):383-92. PubMed ID: 4601668
    [No Abstract]   [Full Text] [Related]  

  • 49. Yoshi 864 (NSC 102627) 1-propanol, 3, 3'-iminodi-dimethanesulfonate (ester) hydrochloride: a phase 1 study.
    Altman SJ; Fletcher WS; Andrews NC; Wilson WL; Pischer T
    Cancer; 1975 Apr; 35(4):1145-7. PubMed ID: 163676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of dianhydrogalactitol in malignant glioma.
    Espana P; Wiernik PH; Walker MD
    Cancer Treat Rep; 1978 Aug; 62(8):1199-200. PubMed ID: 210944
    [No Abstract]   [Full Text] [Related]  

  • 51. Phase II evaluation of galactitol in head and neck cancer: a Southwest Oncology Group Study.
    Haas CD; Lehane D; Bottomley R
    Med Pediatr Oncol; 1983; 11(4):281-3. PubMed ID: 6888328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Preliminary results of clinical trial of the antineoplastic antibiotic bruneomycin].
    Garim AM; Lorie IuI; Reĭzinger MA; Shkarenkov VA; Durnov LA
    Antibiotiki; 1967 Jul; 12(7):609-19. PubMed ID: 4299328
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase II study of hexamethylmelamine (NSC 13875).
    Wilson WL; Schroeder JM; Bisel HF; Mrazek R; Hummel RP
    Cancer; 1969 Jan; 23(1):132-6. PubMed ID: 5812585
    [No Abstract]   [Full Text] [Related]  

  • 54. Investigational drugs for the treatment of malignant melanoma.
    Hellmann K
    Proc R Soc Med; 1974 Feb; 67(2):100-1. PubMed ID: 4821219
    [No Abstract]   [Full Text] [Related]  

  • 55. Combination chemotherapy with adriamycin (NSC-123127) and 1-(2-chloroethyl)-3-cyclohexyl 1-nitrosourea (CCNU; NSC-79037).
    Einhorn LH; Livingston RB; Gottlieb JA
    Cancer Chemother Rep; 1973; 57(4):437-45. PubMed ID: 4586951
    [No Abstract]   [Full Text] [Related]  

  • 56. Phase II trial of vindesine in advanced squamous cell cancer of the head and neck.
    Vogl SE; Camacho FJ; Kaplan BH; O'Donnell MR
    Cancer Treat Rep; 1984 Mar; 68(3):559-60. PubMed ID: 6704987
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase II trial of dianhydrogalactitol in advanced soft tissue and bony sarcomas: a Southwest Oncology Group study.
    Thigpen JT; Samson MK
    Cancer Treat Rep; 1979 Apr; 63(4):553-5. PubMed ID: 445509
    [No Abstract]   [Full Text] [Related]  

  • 58. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
    Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preliminary clinical trial of 1-(2-chlorethyl)-3-(4-methylcyclohexyl)-1 nitrosourea (NSC-95411) (MeCCNU) in human neoplasms.
    Gailani S; Kutcher J
    J Med; 1973; 4(4):209-18. PubMed ID: 4520348
    [No Abstract]   [Full Text] [Related]  

  • 60. Hexamethylmelamine (NSC-13875) in the treatment of primary cancer of the lung with metastasis.
    De la Garza JG; Carr DT; Bisel HF
    Cancer; 1968 Sep; 22(3):571-5. PubMed ID: 5673236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.